Brief: Argenx Preliminary FY Global Product Net Sales $4.15 Bln
12/01/2026 06:05
Jan 12 (Reuters) - argenx SE ARGX.BR: HIGHLIGHTS 2026 STRATEGIC PRIORITIES PRELIMINARY Q4 GLOBAL PRODUCT NET SALES $1.29 BILLION PRELIMINARY FY GLOBAL PRODUCT NET SALES $4.15 BILLION Source text: ID:nGNX9m42YK Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles